Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, announced that the U.S. Environmental Protection Agency (EPA) has purchased five licenses of both its best-in-class GastroPlus™ and ADMET Predictor™ software programs.
John DiBella, vice president of marketing and sales for Simulations Plus, said: “We’re very pleased that the U.S. Environmental Protection Agency has decided to expand their Simulations Plus software licenses by adding multiple licenses of our industry-leading GastroPlus™ and ADMET Predictor™ software packages. Researchers in different divisions at the agency have appreciated how our programs communicate with each other, allowing them to efficiently screen compounds and prioritize testing for several scientific initiatives. We look forward to supporting their efforts and receiving feedback on the development of new predictive methods for animal and human exposure of chemicals, which we continue to see as an important market for our technology.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. For more information, visit our Web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.